Home › Compound Library › Nifedipine (Procardia / Adalat)

Nifedipine (Procardia / Adalat)

Calcium Channel Blockerprescriptionoral · inferred

Dihydropyridine calcium channel blocker for hypertension and angina. Immediate-release formulation has fallen out of favor due to unpredictable absorption and reflex tachycardia. Extended-release (Procardia XL, Adalat CC) formulations are standard. Undergoes extensive hepatic CYP3A4 metabolism.

Projected serum levels — 30 mg, once daily

Nifedipine (Procardia / Adalat)
Nifedipine (Procardia / Adalat) modeled serum levels, 30 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 30 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 10.3 mg, trough ≈ 0.19 mg body load. Population-based estimate over 15 days for a 30 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Calcium Channel Blocker
Route modeled
Oral
Model confidence
inferred
Half-life
2 h
Common dose
30 mg
Suggested maximum
120 mg/day
Reference dose range
15–120 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.12 mg/L at 1 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Nifedipine (Procardia / Adalat) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Nifedipine (Procardia / Adalat) AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Nifedipine (Procardia / Adalat) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Nifedipine (Procardia / Adalat) AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Nifedipine (Procardia / Adalat) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Nifedipine (Procardia / Adalat) AUC by ~5.00x

  • contraindicated
    Diltiazem + Nifedipine (Procardia / Adalat) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Nifedipine (Procardia / Adalat) AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Nifedipine (Procardia / Adalat) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Nifedipine (Procardia / Adalat) AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Nifedipine (Procardia / Adalat) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Nifedipine (Procardia / Adalat) AUC by ~10.00x

Serum checks 241 modeled interaction pairings for nifedipine (procardia / adalat) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Nonlinear first-pass metabolism of nifedipine in healthy subjects Schellens JHM et al. · Xenobiotica, 1991 DOI

    Early PK study demonstrating nonlinear first-pass metabolism of nifedipine with saturable intestinal and hepatic CYP3A4 metabolism.

  2. The pharmacokinetics of extended-release nifedipine: a review Abernethy DR et al. · Journal of Cardiovascular Pharmacology, 1994 DOI

    Comprehensive review of extended-release nifedipine formulations, PK properties, and CYP3A4-based drug interactions.

  3. Grapefruit juice-nifedipine interaction: reproducibility and characterization with the extended release drug formulation Bailey DG et al. · British Journal of Clinical Pharmacology, 1995 DOI

    Demonstration of reproducible 2-3x nifedipine bioavailability increase with grapefruit juice via selective intestinal CYP3A4 downregulation.

3 published studies referenced in the app, each with a plain-language summary.